Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries
Kakaraskoska Boceska B., Vilken T., Xavier BB., Kostyanev T., Lin Q., Lammens C., Ellis S., O’Brien S., da Costa RMA., Cook A., Russell N., Bielicki J., Riddell A., Stohr W., Walker AS., Berezin EN., Roilides E., De Luca M., Romani L., Ballot D., Dramowski A., Wadula J., Lochindarat S., Boonkasidecha S., Namiiro F., Ngoc HTB., Tran MD., Cressey TR., Preedisripipat K., Berkley JA., Musyimi R., Zarras C., Nana T., Whitelaw A., da Silva CB., Jaglal P., Ssengooba W., Saha SK., Islam MS., Mussi-Pinhata MM., Carvalheiro CG., Piddock LJV., Heath PT., Malhotra-Kumar S., Sharland M., Glupczynski Y., Goossens H.
AbstractGram-negative bacteria (GNB) are a major cause of neonatal sepsis in low- and middle-income countries (LMICs). Although the World Health Organization (WHO) reports that over 80% of these sepsis deaths could be prevented through improved treatment, the efficacy of the currently recommended first- and second-line treatment regimens for this condition is increasingly affected by high rates of drug resistance. Here we assess three well known antibiotics, fosfomycin, flomoxef and amikacin, in combination as potential antibiotic treatment regimens by investigating the drug resistance and genetic profiles of commonly isolated GNB causing neonatal sepsis in LMICs. The five most prevalent bacterial isolates in the NeoOBS study (NCT03721302) are Klebsiella pneumoniae, Acinetobacter baumannii, E. coli, Serratia marcescens and Enterobacter cloacae complex. Among these isolates, high levels of ESBL and carbapenemase encoding genes are detected along with resistance to ampicillin, gentamicin and cefotaxime, the current WHO recommended empiric regimens. The three new combinations show excellent in vitro activity against ESBL-producing K. pneumoniae and E. coli isolates. Our data should further inform and support the clinical evaluation of these three antibiotic combinations for the treatment of neonatal sepsis in areas with high rates of multidrug-resistant Gram-negative bacteria.